Abstracts tagged "infusions"

Abstract Number: 2830 • 2019 ACR/ARP Annual Meeting
Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study
Zachary Wallace¹, Tyler Harkness ¹, Xiaoqing Fu ¹, John Stone ², Hyon K. Choi ³ and Rochelle Walensky ¹, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior authorizations (PA) are commonly required by health payers as cost-containment strategies for expensive medications, including infused biologics. In rheumatology, these medications are frequently…
Abstract Number: 2834 • 2018 ACR/ARHP Annual Meeting
The Presence of Anti-Rituximab Antibodies Predicts Infusion-Related Reactions in Patients with Systemic Lupus Erythematosus
Chris Wincup¹, Madhvi Menon¹, Edward Smith², David A. Isenberg¹, Elizabeth Jury³ and Claudia Mauri⁴, ¹University College London, London, United Kingdom, ²Centre for Rheumatology Research, University College London, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom
Background/Purpose: Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody that is commonly used in the treatment of severe and refractory SLE. Although generally well…
Abstract Number: 349 • 2017 ACR/ARHP Annual Meeting
Preferences and Satisfaction in a Pediatric Multidisciplinary Infusion Center
Catherine McDermott &¹, Brian Sohl¹, Lisa M. McGregor² and Lisabeth V. Scalzi³, ¹Penn State Hershey Medical Center, Hershey, PA, ²Penn State Hershey Children’s Hospital, Hershey, PA, ³Department of Rheumatology, Penn State Hershey Children’s Hospital, Hershey, PA
Background/Purpose: Many pediatric rheumatology patients receive infusions in multi-specialty infusion centers (MSICs). There is little data about pediatric patient satisfaction and preferences within MSICs and…
Abstract Number: 545 • 2017 ACR/ARHP Annual Meeting
Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry
Rafat Faraawi¹, Andrew Chow², Majed M M Khraishi³, Derek Haaland⁴, Milton F. Baker⁵, Cathy Tkaczyk⁶, Allen J Lehman⁷, Francois Nantel⁶ and Brendan Osborne⁶, ¹McMaster University, Hamilton, ON, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St John's, NF, Canada, ⁴Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ⁵VIHA, Victoria, BC, Canada, ⁶Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁷Janssen Inc., Toronto, ON, Canada
Background/Purpose: Golimumab (GLM) is a monoclonal antibody targeting TNF-alpha, indicated for the treatment of adults with rheumatoid arthritis in combination with methotrexate (MTX). GLM-IV is…
Abstract Number: 2320 • 2017 ACR/ARHP Annual Meeting
Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years
Annelle Reed¹, Surabhi S. Vinod², Jamelle Maxwell³, Esraa M. A. Eloseily^4,5, Matthew L. Stoll⁴ and Randy Q. Cron⁴, ¹Pediatric rheumatology, Childrens of Alabama, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Childrens of Alabama, Birmingham, AL, ⁴Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, Assiut University, Assiut, Egypt
Background/Purpose: The goals of this report are to describe various therapeutic protocols, volume of intravenous (IV) infusions, and associated adverse events at the University of…
Abstract Number: 159 • 2017 Pediatric Rheumatology Symposium
Preferences and Satisfaction in a Pediatric Multi-specialty Infusion Center
Catherine McDermott &¹, Brian Sohl¹, Lisa M. McGregor², Lisabeth V. Scalzi³ and Barbara E. Ostrov (does not meet authorship criteria)^4,5, ¹Penn State Hershey Medical Center, Hershey, PA, ²Penn State Hershey Children’s Hospital, Hershey, PA, ³Department of Rheumatology, Penn State Hershey Children’s Hospital, Hershey, PA, ⁴Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ⁵Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA
Background/Purpose: Many pediatric rheumatology patients receive infusions in multi-specialty infusion centers (MSICs). There is little data about pediatric patient satisfaction and preferences within MSICs and…
Abstract Number: 751 • 2015 ACR/ARHP Annual Meeting
Rituximab Induced Serum Sickness: A Systematic Review
Paras Karmacharya¹, Dilli Poudel¹, Ranjan Pathak¹, Anthony Donato², Sushil Ghimire¹, Smith Giri³, Madan Aryal¹ and Clifton O. Bingham III⁴, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, WEST READING, PA, ³Internal medicine, University of Tennessee Health Science Center, Memphis, TN, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Rituximab (anti-CD20 monoclonal antibody) has been frequently used to treat various autoimmune diseases in which B-cells are participants, and for hematological malignancies in which…
Abstract Number: 2642 • 2015 ACR/ARHP Annual Meeting
Patient Reported Outcome Assessment of Rheumatoid Arthritis Patients Experience with IV Administered Biologic Therapy
Norman B. Gaylis¹, Joanne Sagliani¹, Danny Tuccitto², Shawn Black³, Kehzen Tang⁴, Raphael Dehoratius^3,5 and Dennis Parenti³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²AARDS Research, Inc, Aventura, FL, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Patient-reported outcomes (PRO) are used to assess patient related benefit in clinical trials. Rheumatoid arthritis (RA) patients are equally receptive to intravenous (IV) or…
Abstract Number: 2768 • 2013 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: 2-Year Results Of a Phase 3 Trial Of Intravenous Golimumab
Michael E. Weinblatt¹, Clifton O. Bingham III², Alan M. Mendelsohn³, Lilianne Kim⁴, Kim Hung Lo⁴, Lenore Noonan³, Daniel Baker⁴ and Rene Westhovens⁵, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of IV GLM 2mg/kg+MTX in active RA despite MTX through wk112. Methods: 592 pts with active RA (≥6/66 SJC,…
Abstract Number: 877 • 2013 ACR/ARHP Annual Meeting
Results From The RATE-RA Study: A Multicenter, Single-Arm Study To Evaluate The Safety Of Administering Rituximab At a More Rapid Infusion Rate In Patients With Rheumatoid Arthritis
Charles H. Pritchard¹, Maria W. Greenwald², Joel M. Kremer³, Norman B. Gaylis⁴, William Rigby⁵, Steve Zlotnick⁶, Carol Chung⁷, Birgit Jaber⁸ and William Reiss⁹, ¹Rheumatology, Drexel University College of Medicine, Willow Grove, PA, ²Desert Medical Advances, Palm Desert, CA, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁵Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁶Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ⁷Genentech Inc., South San Francisco, CA, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Genentech, South San Francisco, CA
Background/Purpose: The FDA-approved dose of rituximab (RTX) in rheumatoid arthritis (RA) is 2 × 1000 mg IV infusions given 2 weeks apart (1 course), with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].